Over the next five years, the introduction of a new set of ARV drugs to a broader global market – including newer drugs and formulations with improved efficacy, tolerability, and safety such as dolutegravir (DTG), tenofovir alafenamide fumarate (TAF) and co-formulated darunavir/ ritonatir (DRV/r) – has the potential to transform the treatment landscape in low- and middle-income countries (LMICs).
ICAP at Columbia University is part of the OPTIMIZE project, a global consortium dedicated to rapidly improving treatment outcomes for people living with HIV by optimizing ARV drugs and formulations and accelerating their introduction in low- and middle-income countries (LMIC).
ICAP has developed the following document that aims to supports country program managers to develop clinical guidance and implementation plans for the introduction of the fixed-dose combination tablet of tenofovir, lamivudine and dolutegravir (TLD). It combines summaries of current normative guidance, available evidence, and programmatic considerations to inform the practical decisions that countries will need to make to develop comprehensive guidance on the use of TLD